focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
I think this award really does bring them into the spotlight, I wouldn't be surprised if we start to see some major traction now. take a listen to the new interview on DT Interviews, you'll see what I mean.
Goodbody Health Inc. (AQSE:GDBY) has today announced that, following its successful rollout of Goodbody testing clinics in the UK, which undertake Blood and Covid PCR testing, it has signed the lease for its first clinic premises in Vancouver, Canada. The clinic is situated in the Burrard Health Centre - a nine storey health-care oriented office building positioned directly across from St. Paul's Hospital. The building is home to numerous doctors, therapists, medical practitioners and other personal service professionals alike and so it is considered an ideal location for the Company to research future opportunities in Canada and roll out the clinic success of the UK.
Geremy Thomas, Executive Chairman, said: "I am delighted to have taken Goodbody clinics across the Atlantic to Canada. I am sure the success Goodbody clinics have had to date in the UK will continue in Canada as well."
The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market
after reading "New weight loss support on the high street" on the NHS website its obvious there is a push to get more people into local pharmacy. This is a definite positive for Goodbody, especially if they are actively engaging customers in health and wellbeing.
Just found this:
Arden Initiating with Buy, 10p PT; Time to move the needle GBDY.PZ
We initiate coverage on Goodbody Health Group with a buy rating and 10p price target. Goodbody is a holistic wellness company embarking on an exciting period of growth. It has recently diversified and repositioned its strategy to deepen its clinical offering and take advantage of the long-term structural themes driving customer attitudes to health and wellbeing - which we believe the market is yet to give it value for. With a 40% ROE, Revenue 20A-23E CAGR of 210%, very strong EBITDA growth and at an 85% valuation discount to industry peers (private clinical lab providers), we’re firm in our view that Goodbody offers great long-term value to investors. Buy.
Key Investment Rationale. We base our thesis on several key factors: (1) A diversified product portfolio, aided by a strong clinical services segment; (2) A supportive policy environment following the implementation of the NHS Long Term plan and (3) Strong wellness thematic tailwinds
Forecasts: growth and profitability to accelerate. We forecast consolidated sales of £16.0m in the upcoming year (FY21E), rising to £35.1m in FY22E and £59.4m in FY23E representing a 3-year CAGR of +210% (FY20A-FY23E). We expect the group to be earnings positive by H1 ’22 and are forecasting an EBITDA 21-23E CAGR of over 300%. We’d expect any margin contractions from changes to mix to be greatly offset by top line increases
Valuation and outlook. We base our price target of 10p on an FY2022E P/E of 11x which implies a FY22E EV/EBITDA of 6.8x – a 178% upside to the current price. We believe this to be justified in light of the projected growth (we forecast gross profit will increase at a 21-23E CAGR of +82.3%), strong returns on capital and the potential for significant upside to our numbers. However, we do acknowledge the early staged nature of this strategy, which brings with it some level of execution risk.
Upcoming Catalysts. We expect full year results for FY21 and Q1 & Q2 financials to form key near term catalysts. The quarterly results in the 1st half of FY22 will provide added insight into how the Group is progressing in executing on its strategy to penetrate the blood testing market. We lay out further catalysts in more detail in the note.
Key Data (GBDY.PZ)
Market Capitalisation £10.9m
Shares in Issue 302.6m
Free Float 65.6%
Average Daily Volume (k) 46
12 Month Trading Range 3p - 7p
for reference Arden rate a BUY a 10% or greater increase in share price expected over 12 months
Thanks for that
@alarno where did you see mention to the app?
anyone been on the new website, there is a new presentation available giving a better idea of whats ahead, I think once this is digested better the share could start moving places
and a change in strategic direction too, sounds very positive to me